Buy rating was Kept at Needham. Surmodics (NASDAQ:SRDX) Has Given Target Of $55.

May 17, 2018 - By Rebecca Betts

Surmodics, Inc. (NASDAQ:SRDX) Corporate Logo

During Q4 2017 the big money sentiment decreased to 0.69. That’s change of 0.25, from 2017Q3’s 0.94. 11 investors sold all, 44 reduced holdings as Surmodics, Inc. ratio dived. 26 grew stakes while 12 funds took stakes. Funds hold 11.07 million shares thus 0.98% less from 2017Q3’s 11.18 million shares.

Legal General Grp Inc Public Limited Company has 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 23,854 shs. 49,119 are owned by Deutsche Natl Bank Ag. Moreover, Alliancebernstein Ltd Partnership has 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 28,921 shs. Jpmorgan Chase holds 30,303 shs or 0% of its capital. California State Teachers Retirement Systems reported 20,389 shs. Millennium Ltd Liability has 0.01% invested in Surmodics, Inc. (NASDAQ:SRDX) for 135,676 shs. Massachusetts-based Arrowstreet Cap Lp has invested 0.01% in Surmodics, Inc. (NASDAQ:SRDX). Vanguard invested 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Price T Rowe Inc Md reported 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Assetmark reported 4 shs or 0% of all its holdings. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). 63,700 were reported by South Dakota Invest Council. Meeder Asset Incorporated has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Invesco Limited stated it has 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Panagora Asset reported 4,039 shs or 0% of all its holdings.

Surmodics, Inc. had 2 selling transactions and 0 insider buys since December 11, 2017. This’s net activity of $63,711.

Reiterated Surmodics (NASDAQ:SRDX) Rating.

New York: On 16 May, analysts note was revealed to investors of Surmodics (NASDAQ:SRDX). Its Buy Rating reiterated by Analysts at Needham. Stock analysts have target price per share of $55 which would suggest 11.79 % upside potential on firm’s stock.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

A total of 2 analysts rate Surmodics (NASDAQ:SRDX) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $5500 highest and $42 lowest target. The avg target $55 is 11.79% above the last ($49.2) price. (NASDAQ:SRDX) has 4 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, February 28 the firm earned “Outperform” rating by Barrington Research. The stock rating was maintained by Needham with “Buy” on Wednesday, May 16. In Wednesday, May 2 report Needham maintained it with “Buy” rating and $4600 target.

SRDX is touching $49.2 during the last trading session, after increased 5.24%.Surmodics, Inc. is uptrending after having risen 61.37% since May 17, 2017. SRDX has 114,997 volume or 113.73% up from normal. The stock outperformed the S&P 500 by 49.82%.

Surmodics, Inc. (NASDAQ:SRDX)’s earnings report is anticipated on August, 2., RTT reports. Analysts forecast $-0.08 earnings per share. That’s $0.17 down or 188.89 % from 2017’s earnings of $0.09. -214.29 % negative EPS growth is what analysts predict. $0.07 earnings per share was revealed for previous quarter.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland.The company has $652.29 million market cap. It operates through two divisions, Medical Device and In Vitro Diagnostics.The P/E ratio is 24600. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

For more Surmodics, Inc. (NASDAQ:SRDX) news posted recently go to:,,, or The titles are as follows: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” posted on May 09, 2018, “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” on May 01, 2018, “Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole …” with a publish date: May 14, 2018, “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” and the last “Biothera Pharmaceuticals Appoints Andrew DC LaFrence Chief Financial Officer” with publication date: May 16, 2018.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.